Coloplast CEO urged to take action: Release the billions!

Medtech firm Coloplast is on a buying spree, but its purchases are too few and far between, according to industry sources. Pharmaceutical firms Novo Nordisk and Lundbeck have led the way so far.

Coloplast CEO Kristian Villumsen | Photo: Stine Bidstrup/ERH

The wealthy and highly lucrative medtech firm Coloplast needs to let go of some of its caution, release the billions and acquire either new firms or technology, according to several industry actors.

"If your strategy involves acquisitions, you have to acquire. Just like if your strategy is to be a digital frontrunner or to be best at marketing. You have to invest in your strategy," says ABG Sundal Collier Jannick Lindegaard Denholt. He is far from alone in his views:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs